Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic

Background: Because of the increasing prevalence of the use of oncolytic orally to patients with malignancies, implementation and monitoring strategies to improve patient safety has become a necessity. Our focus is on the American Society of Oncology Quality Oncology Practice Initiative (QOPI) clinical standards of care, standards of 2.3, and the need for counseling patients before the first administration of oral oncolytic therapy.

Objective: To assess the implementation of strategies for improving the workflow to determine their effect on the number of patients reached for pharmacist counseling prior to the first dose of oral oncolytic drugs.
Methods: In this study a quasi-experimental quality improvement, we formed a multidisciplinary group to develop and implement processes workflow improvements. This process is focused on the redistribution of workflow and application of new technology in EPIC Beacon.

Results: A total of 86 patients were identified as eligible for counseling (38 pre-intervention, post-intervention 48). There was a statistically significant increase in the number of eligible patients counseled in the post-intervention period compared to the pre-intervention period (100% vs 86.84%; 95% CI = -0.212, -0.205; P = 0.017). No significant difference was observed in the number of in-person advising patients or advising patients before the first dose.

Conclusion: Our intervention shows the level of 100% of the advice in the post-intervention period. Further work needs to be done to increase the number of patients we reach before they take their first dose of the drug, as well as the number of patients we can advice face to face.

The relationship between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients who receive intravenous etoposide

The purpose of this study was to describe hypersensitivity reactions with and without the use of in-line filter for intravenous etoposide therapy in pediatric oncology patients. This is a retrospective review of all patients who were treated in the Division of Oncology / Hematology / Bone Marrow Transplant at Children’s Hospital of British Columbia with intravenous etoposide between December 1, 2013 and February 1, 2018. hypersensitivity and anaphylactic reactions associated with infusion of etoposide compared over time, including 12 months earlier, 27 months for use, and for 12 months after the cessation of in-line filtration.

There were 192 patients (average age of 6.0 (IQR 2.8 to 13.0) years were treated with etoposide and etoposide infusion 486 including 137 (28%) previously, 261 (54%) for and 88 (18%) after use filter in-line at our center. twenty-six of 486 (5%) and 13/486 (3%) of infusions resulted in type I hypersensitivity reactions and anaphylaxis, respectively.

There were 2/137 (1%), 36 / 261 (14%.) and 1/88 (1%) infusion reactions before, during and after an in-line filter, each infusion reaction during the period-line filter is higher than during the pre-filter (Z = 3.978; p <0.001) and post-filter (Z = 3.335 ;. p <0.001) in the period of research data show that the use of in-line filtration may be associated with an increased frequency of hypersensitivity reaction to etoposide in pediatric cancer patients.

 Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic
Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic

Why Racial Justice Matters in Radiation Oncology

The recent events have reaffirmed that racism is a pervasive disease disrupt the United States and the infiltration of the fabric of this nation. As health care professionals dedicated to understanding and reduce disease, many radiation oncologists have failed to recognize how structural racism affect the health and well-being of patients we aim to serve. Literature is full of descriptive statistics which show a higher incidence and mortality experienced by the Black population’s health conditions ranging from infant mortality to infectious diseases, including the coronavirus disease in 2019 (COVID-19).

The recognition that the roots of health inequalities experienced by Black people in this country based on racism is essential to move the nation and advanced the field of radiation oncology. With this lens, a brief overview of the structural and institutional racism shape the discussion about what radiation oncologists and their representative organizations can do to cope with this disaster. As a member of the technology, we often use the power of data to improve human health and disease challenge with optimism that approach multidisciplinary effort can result in healing. Some principles to reduce the old problem of the Black marginalization in the field has been recommended by ATIP (Recognition, transparency, intentionality, and representation) and lead (Learn, Engage, Advocate, Advocate, Support) approach.

However, additional introspection recommended. Just like individuals, practices and organizations rallied to determine how best to address the problems associated with the 19th COVID pandemic, studied the same spirit should be applied to the issue of racism to combat this evil and often deadly disease.

Nurse-led oral and maxillofacial oncology clinic: a review

The oral and maxillofacial (OMFS) head “nurse-led” and neck (H & N) clinics have been introduced and developed over the last decade, and we are now close to the point that this effort could potentially be applied nationally. This paper is a systematic review of the proposed clinical models OMFS H & N nurse-led.

EG-VEGF Blocking Peptide

20-abx064278
  • EUR 272.00
  • EUR 411.00
  • 1 mg
  • 5 mg
  • Shipped within 5-10 working days.

anti- VEGF antibody

FNab09391 100µg
EUR 548.75
  • Recommended dilution: WB: 1:200-1:2000
  • IF: 1:10-1:100
  • IHC: 1:50-1:500
  • Immunogen: vascular endothelial growth factor A
  • Uniprot ID: P15692
  • Gene ID: 7422
  • Research Area: Signal Transduction, Cardiovascular, Cancer, Immunology, Developmental biology
Description: Antibody raised against VEGF

Anti- VEGF antibody

FNab09933 100µg
EUR 548.75
  • Recommended dilution: WB: 1:1000-1:4000
  • IHC: 1:50-1:500
  • Immunogen: vascular endothelial growth factor A
  • Uniprot ID: P15692
  • Research Area: Signal Transduction, Cardiovascular, Cancer, Immunology, Developmental biology
Description: Antibody raised against VEGF

Anti-VEGF antibody

PAab09391 100 ug
EUR 386

Anti-VEGF antibody

STJ119887 100 µl
EUR 393
Description: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.

Anti-VEGF antibody

STJ97787 200 µl
EUR 197
Description: Rabbit polyclonal to VEGF.

VEGF-KDR, Peptide Aptamer, Biotinylated

AP-337-B 1 mg Ask for price

VEGF-KDR, Peptide Aptamer, unlabeled

AP-337-U 5 mg Ask for price

VEGF Receptor 2 Blocking Peptide

AF4726-BP 1mg
EUR 195

Anti-VEGF/VEGF164 Antibody

A00045-1 100ug/vial
EUR 294

Anti-VEGF/Vegfa Antibody

A00045-2 100ug/vial
EUR 294

Anti-VEGF-C Antibody

A00623 100ul
EUR 397
Description: Rabbit Polyclonal Antibody for VEGF-C Antibody (VEGFC) detection.tested for IHC, WB in Human, Mouse, Rat.

Anti-VEGF/VEGFA Antibody

PA1080 100ug/vial
EUR 334

Anti-VEGF/VEGFA Antibody

PB9071 100ug/vial
EUR 334

Anti-VEGF-C antibody

STJ96662 200 µl
EUR 197
Description: Rabbit polyclonal to VEGF-C.

Anti-VEGF-B antibody

STJ96851 200 µl
EUR 197
Description: Rabbit polyclonal to VEGF-B.

anti-VEGF Receptor 1

YF-PA11817 50 ug
EUR 363
Description: Mouse polyclonal to VEGF Receptor 1

anti-VEGF Receptor 1

YF-PA11818 100 ug
EUR 403
Description: Rabbit polyclonal to VEGF Receptor 1

anti-VEGF Receptor 3

YF-PA23727 50 ul
EUR 334
Description: Mouse polyclonal to VEGF Receptor 3

Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug

7422-MSM1-P1 100ug
EUR 428

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Hu-48T 48T
EUR 336
  • Should the Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Hu-96T 96T
EUR 425
  • Should the Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Hu-48Tests 48 Tests
EUR 330

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Hu-96Tests 96 Tests
EUR 450

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Hu-48Tests 48 Tests
EUR 317

Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Hu-96Tests 96 Tests
EUR 431

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

VEGF mimotope (avastin binding peptide) M074_F02

200-851-P 100 ug
EUR 164

VEGF mimotope (avastin binding peptide) M074_D12

200-852-P 100 ug
EUR 164

VEGF-KDR, Peptide Aptamer, FITC labelled

AP-337-F 1 mg Ask for price

Human C-Peptide ELISA Kit

DLR-C-Peptide-Hu-48T 48T
EUR 398
  • Should the Human C-Peptide ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human C-Peptide ELISA Kit

DLR-C-Peptide-Hu-96T 96T
EUR 511
  • Should the Human C-Peptide ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human C-Peptide ELISA Kit

RDR-C-Peptide-Hu-48Tests 48 Tests
EUR 404

Human C-Peptide ELISA Kit

RDR-C-Peptide-Hu-96Tests 96 Tests
EUR 556

Human C-Peptide ELISA Kit

RD-C-Peptide-Hu-48Tests 48 Tests
EUR 387

Human C-Peptide ELISA Kit

RD-C-Peptide-Hu-96Tests 96 Tests
EUR 532

Anti-VEGF (Bevacizumab), humanized Antibody

A1045-100
EUR 501

Anti-VEGF Rabbit Monoclonal Antibody

M00045-1 100ug/vial
EUR 397
Description: Rabbit Monoclonal VEGF Antibody. Validated in Flow Cytometry, IP, IF, IHC, ICC and tested in Human, Mouse.

Anti-VEGF Receptor 3 (5B6)

YF-MA10355 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (5F11)

YF-MA13094 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (6F9)

YF-MA13095 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (5B5)

YF-MA13096 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (4D1)

YF-MA13097 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (2E3)

YF-MA13098 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (1C1)

YF-MA13099 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 3 (6B7)

YF-MA13100 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3

Anti-VEGF Receptor 2 (2A2)

YF-MA13909 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4A2)

YF-MA13910 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (2C5)

YF-MA13911 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4B5)

YF-MA13912 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF Receptor 2 (4F1)

YF-MA13913 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2

Anti-VEGF-A Humanized Antibody

A2136-100 100 µg
EUR 510

Phospho-VEGF Receptor 2 (Tyr1175) Blocking Peptide

AF4426-BP 1mg
EUR 195

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-b-48T 48T
EUR 493
  • Should the Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids.

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-b-96T 96T
EUR 641
  • Should the Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids.

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Mu-48T 48T
EUR 435
  • Should the Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Mu-96T 96T
EUR 561
  • Should the Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Ra-48T 48T
EUR 454
  • Should the Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

DLR-EG-VEGF-Ra-96T 96T
EUR 587
  • Should the Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-b-48Tests 48 Tests
EUR 516

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-b-96Tests 96 Tests
EUR 716

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Mu-48Tests 48 Tests
EUR 447

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Mu-96Tests 96 Tests
EUR 618

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Ra-48Tests 48 Tests
EUR 470

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RDR-EG-VEGF-Ra-96Tests 96 Tests
EUR 651

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-b-48Tests 48 Tests
EUR 494

Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-b-96Tests 96 Tests
EUR 684

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Mu-48Tests 48 Tests
EUR 429

Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Mu-96Tests 96 Tests
EUR 591

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Ra-48Tests 48 Tests
EUR 450

Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit

RD-EG-VEGF-Ra-96Tests 96 Tests
EUR 622

VEGF

LF-PR009 10 ug
EUR 255
Description: VEGF protein

VEGF

MO15067 500 ug
EUR 910

VEGF

PR15028 10 ug
EUR 461

Human VEGF Protein

abx060229-100ug 100 ug
EUR 787
  • Shipped within 5-10 working days.

human VEGF Antibody

E13-a001 100μg
EUR 382

VEGF/ Rat VEGF ELISA Kit

ELA-E0143r 96 Tests
EUR 886

VEGF-A(VEGF/1063) Antibody

BNUM1063-50 50uL
EUR 395
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL

VEGF-A(VEGF/1063) Antibody

BNUB1063-100 100uL
EUR 209
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody

BNUB1063-500 500uL
EUR 458
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody

BNC551063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC551063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC611063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC611063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC471063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC471063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC051063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC051063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC401063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC401063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC431063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC431063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC041063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC041063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC801063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC801063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCP1063-250 250uL
EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCR1063-250 250uL
EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCA1063-250 250uL
EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCAP1063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCAP1063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCB1063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCB1063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCH1063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCH1063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC881063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC881063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC941063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC941063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC681063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC681063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC701063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC701063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC811063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC811063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

Anti-VEGF Receptor 2/KDR Antibody

A00901-2 100ug/vial
EUR 334

Anti-VEGF Receptor 2/Kdr Antibody

A00901-3 100ug/vial
EUR 334

Anti-VEGF Receptor 3/FLT4 Antibody

A01276-2 100ug/vial
EUR 334

Anti-VEGF Receptor 3/FLT4 Antibody

A01276-3 100ug/vial
EUR 334

Anti-VEGF Receptor 1/FLT1 Antibody

A00534 100ug/vial
EUR 294

Anti-VEGF Receptor 1/FLT1 Antibody

A00534-1 100ug/vial
EUR 294

Anti-VEGF Receptor 1/FLT1 Antibody

PA1399 100ug/vial
EUR 294

Anti-VEGF Receptor 1/FLT1 Antibody

PA1966 100ug/vial
EUR 294

Anti-VEGF Receptor 1/FLT1 Antibody

PA1966-1 100ug/vial
EUR 294

Anti-VEGF Receptor 1/FLT1 Antibody

PA1966-2 100ug/vial
EUR 294

Anti-VEGF Receptor 2/KDR Antibody

PA1989 100ug/vial
EUR 334

Anti-VEGF Receptor 2/KDR Antibody

PB9429 100ug/vial
EUR 294

Mouse Anti Human Vegf Receptor 1 Monoclonal Antibody

CABT-47861MH 0.1 mg
EUR 892

Mouse Anti-Human VEGF monoclonal antibody, clone JID793

CABT-L3034-100uL500uL 100 uL, 500 uL
EUR 502

VEGF receptor Flt-1 (F56), Peptide Aptamer, Biotinylated

AP-334-B 1 mg Ask for price

VEGF receptor Flt-1 (F56), Peptide Aptamer, unlabeled

AP-334-U 5 mg Ask for price

The literature on the topic is limited: only eight papers were eligible were identified and reviewed. The rated focuses on four domains: requirements / needs, actual costs, patient safety and outcomes, and education and training. Most of the advantages / benefits of the proposed clinic had previously been discussed. The current review has revealed that the published evidence available on the clinical concept OMFS H & N nurse led indicate that they may not be necessary.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *